RT Book, Section
A1 Howland, Mary Ann
A1 Smith, Silas W.
A2 Nelson, Lewis S.
A2 Howland, Mary Ann
A2 Lewin, Neal A.
A2 Smith, Silas W.
A2 Goldfrank, Lewis R.
A2 Hoffman, Robert S.
SR Print(0)
ID 1163002685
T1 Glucagon
T2 Goldfrank's Toxicologic Emergencies, 11e
YR 2019
FD 2019
PB McGraw-Hill Education
PP New York, NY
SN 9781259859618
LK accessemergencymedicine.mhmedical.com/content.aspx?aid=1163002685
RD 2024/04/20
AB The  traditional  role  of  glucagon  was  to  reverse  life-threatening  hypoglycemia  in  patients  with  diabetes  unable  to  receive  dextrose  in  the  outpatient  setting.  However,  in  clinical  toxicology,  glucagon  is  used  early  in  the  management  of  β-adrenergic  antagonist  and  calcium  channel  blocker  toxicity  to  increase  heart  rate,  contractility,  and  blood  pressure  by  increasing  myocardial  cyclic  adenosine  monophosphate  (cAMP)  via  a  non–β-adrenergic  receptor  mechanism  of  action.  The  use  of  glucagon  is  based  primarily  on  animal  studies  as  well  as  human  case  series  and  case  reports.  The  effects  of  glucagon  are  often  transient.